The Economics of Psychedelic Investing

This half day event will explore the quickly emerging industry of psychedelic medicines and the companies looking to capitalize on it. Several cities have decriminalized medical mushrooms, but the plant remains federally illegal and like cannabis is a schedule 1 drug.

Research has shown psilocybin to help relieve symptoms for people who experience cluster headaches, treat addiction, and could be an alternative to typical depression treatments in the general population. According to the 2017 Global Drug Survey, mushrooms are the safest recreational drug to use.

These panels will educate curious investors as to the opportunities to invest in this industry in its earliest stages.